Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study

A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis

(2015) Maria Theresa Arias et al.   Clinical Gastroenterology and Hepatology

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease

(2015) Janet R. Wade et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study

(2014) W. J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

P-147 Clinical Efficacy of Certolizumab Pegol in Patients With Crohn’s Disease Based on Moderate versus Severe Activity in the PRECiSE-2 Trial

(2014) Stephen Hanauer et al.   INFLAMMATORY BOWEL DISEASES

Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms

(2012) I Ordás et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol

(2012) Xavier Hébuterne et al.   GUT

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

(2011) L. S. Kiss et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

(2011) Edouard Louis et al.   GASTROENTEROLOGY

Long-term durability of response to adalimumab in Crohnʼs disease

(2011) M. Chaparro et al.   INFLAMMATORY BOWEL DISEASES

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis

(2011) A.A. Fasanmade et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data

(2010) Stefan Schreiber et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study

(2010) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Risk factors for metabolic bone disease in Crohnʼs disease patients

(2010) Marília Cravo et al.   INFLAMMATORY BOWEL DISEASES